What is the recommended treatment plan for an adult with heart failure secondary to congenital heart disease, including guideline‑directed medical therapy, referral to an adult congenital heart disease center, and consideration of device or surgical interventions?

Heart Failure Secondary to Congenital Heart Disease

All adults with heart failure secondary to congenital heart disease must be referred immediately to a specialized Adult Congenital Heart Disease (ACHD) center, as patients managed at ACHD centers have demonstrably better outcomes than those cared for elsewhere. 1

Immediate Referral to ACHD Center

• Referral to an ACHD center is the single most critical intervention for any adult with heart failure from congenital heart disease, regardless of symptom severity, because the heterogeneity of anatomic defects and surgical repairs requires specialized expertise that general cardiologists typically lack. 1

• ACHD centers provide integrated multidisciplinary services including CHD-specific echocardiography, specialized cardiac catheterization, electrophysiology with CHD experience, advanced cardiac imaging (CMR, CT), and cardiac anesthesiology trained in congenital defects. 2, 3

• Every cardiovascular provider should establish a referral relationship with a regional ACHD center to ensure geographically accessible specialized care for all patients. 1

Guideline-Directed Medical Therapy (GDMT)

For Systemic Left Ventricle Heart Failure

• Standard heart failure medications (ACE inhibitors/ARBs, beta-blockers, aldosterone antagonists) should be initiated when the failing ventricle is a systemic left ventricle, as data from acquired heart disease populations apply to this subset of ACHD patients. 1, 3

• Loop diuretics are first-line therapy for volume overload, peripheral edema, and pulmonary congestion, with intravenous administration for acute decompensation. 3

• Salt restriction (≤2 g/day) and fluid restriction (approximately 1.5 L/day) should be implemented to support diuretic efficacy. 3

For Systemic Right Ventricle or Single Ventricle Physiology

• Evidence for standard GDMT in systemic right ventricles and Fontan circulation is currently lacking, representing a major knowledge gap, though these medications are often empirically used. 1, 4, 5

• Medical therapy should be attempted cautiously in systemic right ventricle patients (e.g., transposition after atrial switch, congenitally corrected TGA) under ACHD specialist guidance, as tolerance and efficacy remain uncertain. 1

• Newer agents such as ARNI (angiotensin receptor-neprilysin inhibitors) or SGLT2 inhibitors may show benefit but require further study in this population. 4

Comprehensive Diagnostic Assessment

Imaging Protocol

• Transthoracic echocardiography performed by clinicians trained in congenital heart disease is the primary imaging modality for initial and serial assessment of ventricular function, valve regurgitation, and hemodynamic sequelae. 2, 3, 6

• Cardiac MRI is essential for quantitative assessment of right ventricular size and function, serial monitoring based on anatomic complexity, and evaluation of thoracic aortic aneurysms beyond echocardiographic windows. 2

• Transesophageal echocardiography should be performed when transthoracic windows are inadequate or to exclude atrial thrombus before invasive procedures. 3

Hemodynamic Evaluation

• Cardiac catheterization at an ACHD-experienced center is indicated to measure pulmonary artery pressures, calculate pulmonary vascular resistance, detect intracardiac shunts, and assess operability. 3

• Cardiopulmonary exercise testing (CPET) provides objective assessment of functional capacity and may predict mortality risk in certain lesions. 1

• Biomarkers (BNP/NT-proBNP) and electrocardiography should be obtained to detect sinus node dysfunction, intra-atrial reentry tachycardia, and atrioventricular block progression. 2

Device and Surgical Interventions

Arrhythmia Management

• Implantable cardioverter-defibrillator (ICD) placement should be considered for primary prevention in high-risk patients, though specific criteria for ACHD populations remain under investigation. 1

• Cardiac resynchronization therapy (CRT) is reasonable in appropriately selected patients with systemic ventricular dysfunction and conduction delay, though optimal pacing strategies in ACHD require further study. 1

• Catheter ablation has emerged as an excellent early therapeutic option for arrhythmias in experienced ACHD centers using 3-dimensional mapping technology. 1

Surgical Considerations

• After detailed anatomic and hemodynamic assessment, referral to a cardiac surgeon with CHD expertise is required to evaluate feasibility of surgical repair of structural defects causing heart failure. 3

• Timing of intervention depends on lesion-specific criteria: for example, pulmonary valve replacement in tetralogy of Fallot, tricuspid valve surgery in systemic right ventricles, or revision of Fontan pathways. 1

Advanced Heart Failure Therapies

• Mechanical circulatory support (ventricular assist devices) has emerged as a feasible option in highly selected ACHD patients, though anatomic complexity poses significant challenges. 7, 4

• Heart transplantation should be considered when medical and surgical options are exhausted, with evaluation including assessment of antibodies from prior surgeries and multisystem dysfunction (renal, hepatic, pulmonary). 1

• Dual-organ transplantation (heart-liver or heart-lung) may be necessary in patients with Eisenmenger syndrome or failing Fontan with hepatic cirrhosis. 1

Critical Management Caveats

• Anticoagulation decisions are complex: warfarin should be withheld during coagulopathy or elevated INR from hepatic congestion, and direct oral anticoagulants lack sufficient data in ACHD populations. 1, 3

• Endocarditis prophylaxis is NOT routinely indicated for most unrepaired or repaired CHD unless highest-risk conditions exist (prosthetic valves, prior endocarditis, unrepaired cyanotic CHD). 6

• Renal function must be assessed before prescribing medications, as patients with complex CHD may have end-organ dysfunction, and cyanotic patients require special consideration for any medication due to altered physiology. 2

• Radiation exposure should be minimized during imaging, with non-ionizing modalities (echocardiography, CMR) chosen whenever appropriate. 2

• Pericardiocentesis is not routinely indicated for pericardial effusions unless signs of tamponade develop; aggressive diuretic therapy often resolves heart-failure-related effusions. 3

Long-Term Follow-Up Strategy

• Serial assessment frequency depends on anatomic complexity and physiological stage, with patients classified using the ACHD Anatomic and Physiological (AP) classification system that incorporates both structural defects and current hemodynamic status. 1, 2

• Every ACHD patient should have a primary care physician with current clinical records on file at both the primary care office and the regional ACHD center, and patients should carry a complete medical "passport" with their history and contact information. 1

• Close interaction between ACHD programs and adult heart failure services is necessary to ensure structured approach to end-stage heart failure, with early consideration for transplant listing when appropriate. 1